Replies to post #129266 on Biotech Values

[oc631]

Incivek will be dosed BID (rather than TID), which will soon be the de facto standard for all patients who take Incivek.

Would VRTX achieve a higher SVR rate with TID dosing for 12 weeks? The main strategy here could be to rekindle waning investor interest in their HCV program by pushing the limits of the drug after approval. Cherry picking CC patients with the focus on BID dosing for 12 weeks does give VRTX investors something to look forward to if scripts start to flatten or fall next year.